Triazavirin

Triazavirin
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name 2-methylsulfanyl-6-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-7(4H)-one;
CAS Number	928659-17-0 ;
PubChem CID	3113817;
ChemSpider	2367718;
CompTox Dashboard (EPA)	DTXSID40389402 ;
ECHA InfoCard	100.217.074
Chemical and physical data
Formula	C5H4N6O3S
Molar mass	228.189 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CSc1[nH]n2c(=O)c(nnc2n1)[N+](=O)[O-];
	InChI InChI=1S/C5H4N6O3S/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5/h1H3,(H,6,8,9); Key:IDVQGNMSSHPZSJ-UHFFFAOYSA-N;

Triazavirin (TZV) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.[1] It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity.[2][3][4] However triazavirin has also been found to have antiviral activity against a number of other viruses including TBEV,[5] and is also being investigated for potential application against Lassa fever and Ebola virus disease.[6][7][8][9][10]

References

Rusinov VL, Sapozhnikova IM, Ulomskii EN, Medvedeva NR, Egorov VV, Kiselev OI, et al. (2015). "Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins". Chemistry of Heterocyclic Compounds. 51 (3): 275–280. doi:10.1007/s10593-015-1695-4.
Loginova SI, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, et al. (2007). "[Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 52 (11–12): 18–20. PMID 19275052.
Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, et al. (May 2010). "Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication". Antimicrobial Agents and Chemotherapy. 54 (5): 2017–22. doi:10.1128/AAC.01186-09. PMC 2863629. PMID 20194696.
Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, et al. (2012). "[A new antiviral drug Triazavirin: results of phase II clinical trial]". Voprosy Virusologii (in Russian). 57 (6): 9–12. PMID 23477247.
Loginova SI, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON (2014). "[Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 59 (1–2): 3–5. PMID 25051708.
"Target: Ebola". Pravda. Retrieved 18 January 2015.
"Yekaterinburg pharmacies to sell domestic antiviral drug". Retrieved 18 January 2015.
"Ebola crisis: Vaccine 'too late' for outbreak. BBC News, 17 October 2014". BBC News.
Kukil Bora. Russia Will Begin Testing Triazavirin, Used For Lassa Fever, And Other Drugs On Ebola: Health Ministry. International Business Times, 12 November 2014
Darya Kezina. New antiviral drug from Urals will help fight Ebola and other viruses. Russia Beyond the Headlines, 12 November 2014

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Rusinov VL, Sapozhnikova IM, Ulomskii EN, Medvedeva NR, Egorov VV, Kiselev OI, et al. (2015). "Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins". Chemistry of Heterocyclic Compounds. 51 (3): 275–280. doi:10.1007/s10593-015-1695-4.

[pmid19275052-2] Loginova SI, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, et al. (2007). "[Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 52 (11–12): 18–20. PMID 19275052.

[pmid20194696-3] Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, et al. (May 2010). "Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication". Antimicrobial Agents and Chemotherapy. 54 (5): 2017–22. doi:10.1128/AAC.01186-09. PMC 2863629. PMID 20194696.

[pmid23477247-4] Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, et al. (2012). "[A new antiviral drug Triazavirin: results of phase II clinical trial]". Voprosy Virusologii (in Russian). 57 (6): 9–12. PMID 23477247.

[pmid25051708-5] Loginova SI, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON (2014). "[Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 59 (1–2): 3–5. PMID 25051708.

[6] "Target: Ebola". Pravda. Retrieved 18 January 2015.

[7] "Yekaterinburg pharmacies to sell domestic antiviral drug". Retrieved 18 January 2015.

[8] "Ebola crisis: Vaccine 'too late' for outbreak. BBC News, 17 October 2014". BBC News.

[9] Kukil Bora. Russia Will Begin Testing Triazavirin, Used For Lassa Fever, And Other Drugs On Ebola: Health Ministry. International Business Times, 12 November 2014

[10] Darya Kezina. New antiviral drug from Urals will help fight Ebola and other viruses. Russia Beyond the Headlines, 12 November 2014

Triazavirin

See also

References